Want to see TNYA full AI Analyst Report?
TNYA Stock Chart & Stats
$1.33
-$0.05(-3.69%)
At close: 4:00 PM EST
$1.33
-$0.05(-3.69%)
Day’s Range― - ―
52-Week Range$0.53 - $2.35
Previous CloseN/A
Volume1.07M
Average Volume (3M)4.00M
Market Cap
$165.35M
Enterprise Value$86.67
Total Cash (Recent Filing)$78.08M
Total Debt (Recent Filing)$3.95M
Price to Earnings (P/E)―
Beta2.71
Next Earnings
Nov 11, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding224,230,010
10 Day Avg. Volume2,873,734
30 Day Avg. Volume4,003,933
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.88
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.33Price Target Upside676.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$10.21M
Bulls Say, Bears Say
Bulls Say
Conservative LeverageLow absolute debt and a very low debt-to-equity ratio materially reduce near-term refinancing and interest-rate risks for a pre-commercial biotech. This conservatism preserves optionality to fund clinical programs via equity or partnerships and limits fixed-cost strain during multi-year development timelines.
Multi-modality PipelineA diversified R&D approach across gene, cell and small-molecule modalities creates multiple independent value drivers and lowers single-program binary risk. Structurally, platform breadth increases probability of clinical success, supports strategic partnerships, and builds durable competitive advantages if any modality reaches pivotal or commercial stages.
Outsourced Manufacturing StrategyMoving from an owned large facility to CDMO partners reduces fixed overhead, capital expenditures and long-term lease commitments. This operational flexibility improves capital efficiency, enables scalable supply for late-stage trials or commercialization, and allows focus on core R&D and assay/process expertise retained internally.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow require recurring capital raises or material partner funding to sustain development. Over 2-6 months this reduces strategic flexibility, increases dilution risk, and can force prioritization or delays in clinical programs absent secured financing or milestone-based partnerships.
Large Continuing LossesDeep negative net income and operating losses reflect heavy R&D and operating investments without product revenues. This structural loss profile means the company will remain dependent on external financing until commercialization, increasing execution risk if trial timelines slip or development requires more capital than anticipated.
Expanded Equity Incentive DilutionShareholder approval to expand the incentive plan improves recruitment but raises durable dilution risk: a one-time 6.5M share increase plus removal of a cap increases long-term share issuance flexibility. Over time this can meaningfully dilute existing holders and affect per-share economics as additional awards are granted.
Tenaya Therapeutics News
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.53 and its highest was $2.35 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $165.35M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 90 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.068 by -$0.132.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 224,230,010 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.068. Following the earnings report the stock price went down -7.526%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenaya Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (676.94% Upside)
$10.33 (676.94% Upside)
Blogger Sentiment
Bullish
TNYA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.42%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage biotechnology company focused on discovering, developing, and potentially commercializing therapies for heart disease. The company applies multiple therapeutic modalities—including gene therapy, cell therapy, and small molecules—to address genetic and acquired cardiovascular conditions, with a pipeline centered on targeted treatments intended to modify or correct underlying disease mechanisms rather than only manage symptoms.
TNYA Stock 12 Month Forecast
Average Price Target
$10.33
▲(676.94% Upside)
Technical Analysis
Galectin Therapeutics
―
Abeona Therapeutics
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Candel Therapeutics
―
Ownership Overview
22.59% Insiders
4.44% Mutual Funds
2.90% Other Institutional Investors
65.90% Public Companies and Individual Investors